Role of calcium metabolism in premenstrual syndrome

References

• Simon H. Mind and Madness in Ancient Greece. Cornell University Press, Ithaca, NY, USA (1978).
   Google Scholar
• Studd J. Ovariotomy for menstrual madness and premenstrual syndrome; 19th Century history and lessons for current practice. Gynecol. Endocrinol.22, 411–415 (2006).
   PubMed Web of Science ®Google Scholar
• Frank RT. The hormonal causes of premenstrual tension. Arch. Neurol. Psychiatry26, 1053–1057 (1931).
   Google Scholar
• Greene R, Dalton K. The premenstrual syndrome. BMJ1(4818), 1007–1014 (1953).
   PubMed Web of Science ®Google Scholar
• Braverman PK. Premenstrual syndrome and premenstrual dysphoric disorder. J. Pediatr. Adolesc. Gynecol.20(1), 3–12 (2007).
   PubMed Web of Science ®Google Scholar
• Halbreich U, Borenstein J, Pearlstein T, Kahn LS. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology28, 1–23 (2003).
   PubMed Web of Science ®Google Scholar
• Borer M, Bhanot V. Hyperparathyroidsim: neuropsychiatric manifestations. Psychosomatics26, 597–601 (1985).
   PubMed Web of Science ®Google Scholar
• Carman JS, Wyatt RJ. Alterations in cerebrospinal fluid and serum total calcium with changes in psychiatric state. In: Neuroregulators and Psychiatric Disorders. Usdin E, Hamburg DA, Barchas JD (Eds). Oxford University Press, NY, USA 488–494 (1977).
   Google Scholar
• Tohme J, Bilezikian JP. Diagnosis and treatment of hypocalcemic emergencies. Endocrinologist6, 10–18 (1996).
   Google Scholar
• Cogan MD, Covey CM, Arieff A, Wisniewski A, Clark OH. Central nervous system manifestations of hyperparathyroidism. Am. J. Med.65, 963–969 (1978).
   PubMed Web of Science ®Google Scholar
• Jimerson DC, Post R, Carman JS, van Kammen DP, Wood JH, Goodwin FK. CSF calcium: clinical correlates in affective illness and schizophrenia. Biol. Psychiatry14, 37–51 (1979).
   PubMed Web of Science ®Google Scholar
• Aurbach G, Marx S, Spiegel A. Parathyroid hormone, calcitonin, and the calciferols. In: Textbook of Endocrinology (8th Edition). Williams RH (Ed.). Saunders, PA, USA 1397–1517 (1992).
   Google Scholar
• Weston PG, Howard MQ. The determination of sodium, potassium, calcium and magnesium in the blood and spinal fluid of patients suffering from manic depressive insanity. Arch. Neurol. Psychiatry8, 179–183 (1922).
   Google Scholar
• Thys-Jacobs S, McMahon D, Bilezikian JP. Cyclic changes in calcium metabolism across the menstrual cycle in women with premenstrual dysphoric disorder. J. Clin. Endocrinol. Metab.92, 2952–2959 (2007).
   PubMed Web of Science ®Google Scholar
• Aedo AR, Langren BM, Cekan Z, Diczfalusy E. Studies on the pattern of circulating steroids in the normal menstrual cycle. Acta Endocrinol. (Copenh.)82, 600–616 (1976).
   PubMedGoogle Scholar
• Urban RJ, Veldhuis JD, Dufau ML. Estrogen regulates the GnRH-stimulated secretion of biologically active LH. J. Clin. Endocrinol. Metab.72, 660–668 (1991).
   PubMed Web of Science ®Google Scholar
• Rubinow DR, Hoban MC, Grover GN et al. Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects. Am. J. Obstet. Gynecol.158, 5–11 (1988).
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Genazzani AD, Martignoni E, Fioroni L, Sances G, Genazzani AR. Neuroendocrine correlates of premenstrual syndrome: changes in the pulsatile pattern of plasma LH. Psychoneuroendocrinology15, 269–277 (1990).
   PubMed Web of Science ®Google Scholar
• Cerin A, Collins A, Landgren BM, Eneroth P. Hormonal and biochemical profiles of premenstrual syndrome. Acta Obstet. Gynecol. Scand.72, 337–343 (1993).
   PubMed Web of Science ®Google Scholar
• Roca CA, Schmidt PJ, Bloch M et al. Implications of endocrine studies of premenstrual syndrome. Psychiatr. Ann.26, 576–480 (1996).
   Web of Science ®Google Scholar
• Muse KN, Cetel NS, Futterman LA, Yen SC. The premenstrual syndrome. Effects of “medical ovariectomy”. N. Engl. J. Med.311(21), 1345–1349 (1984).
   PubMed Web of Science ®Google Scholar
• Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral efforts of gonadal steroids in women with and in those without premenstrual syndrome. N. Engl. J. Med.338, 209–216 (1998).
   PubMed Web of Science ®Google Scholar
• Mortola JF, Girton L, Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin. J. Clin. Endocrinol. Metab.71, 252A–252F (1991).
   Web of Science ®Google Scholar
• Casson P, Hahn PM, Van Vugt DA, Reid RL. Lasting response to ovariectomy in severe intractable premenstrual syndrome. Am. J. Obstet. Gynecol.162, 99–105 (1990).
   PubMed Web of Science ®Google Scholar
• Magos AL, Brincat M, Studd JW. Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone. BMJ292, 1629–1633 (1986).
   PubMed Web of Science ®Google Scholar
• Watson NR, Studd JW, Savvas M, Garnett T, Baber RJ. Treatment of severe premenstrual syndrome with estradiol patches and cyclical oral norethisterone. Lancet2, 730–732 (1989).
   PubMed Web of Science ®Google Scholar
• Smith RN, Studd JW, Zamblera D, Holland EF. A randomized comparison over 8 months of 100 microgram and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br. J. Obstet. Gynaecol.102, 745–484 (1995).
   Google Scholar
• Wyatt K, Dimmock PW, O’Brian PM. Premenstrual syndrome. In: Clinical Evidence (4th Issue). Barton S (Ed.). BMJ Publishing Group, London, UK 1121–1233 (2000).
   Google Scholar
• Baker ER, Best RG, Manfred RL, Demers LM, Wolf GC. Efficacy of progesterone vaginal suppositories in alleviation of nervous symptoms inpatients with premenstrual syndrome. J. Assist. Reprod. Genet.12, 205–209 (1995).
   PubMed Web of Science ®Google Scholar
• Steiner M. Female specific mood disorders. Clin. Obstet. Gynecol.35, 599–611 (1992).
   PubMed Web of Science ®Google Scholar
• Rojansky N, Halbreich U, Zander K, Barkai A, Goldstein S. Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes. Gynecol. Obstet. Invest.31, 146–152 (1991).
   PubMed Web of Science ®Google Scholar
• De Barardis D, Serroni N, Salerno RM, Ferro FP. Treatment of premenstrual dysphoric disorder (PMDD) with a novel formulation of drospirenone and ethinyl estradiol. Ther. Clin. Risk Manag.3(4), 585–590 (2007)
   PubMedGoogle Scholar
• Biegon A, Bercovitz H, Samuel D. Serotonin receptor concentration during the estrous cycle of the rat. Brain Res.187, 221–225 (1980).
   PubMed Web of Science ®Google Scholar
• Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science232, 1004–1007 (1986).
   PubMed Web of Science ®Google Scholar
• Steiner M, Steinberg S, Stewart D et al. Fluoxetine in the treatment of premenstrual dysphoria. N. Engl. J. Med.332, 1529–1534 (1995).
   PubMed Web of Science ®Google Scholar
• Yonkers KA, Halbreich U, Freeman E et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. JAMA278, 983–988 (1997).
   PubMed Web of Science ®Google Scholar
• Young MN, Nordin BEC. Effect of natural and artificial menopause on plasma and urinary calcium and phosphorus. Lancet2, 118 (1967).
   Web of Science ®Google Scholar
• Young SA, Hurt PH, Benedek DM, Howard RS. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase. J. Clin. Psychiatry59, 76–80 (1998).
   PubMed Web of Science ®Google Scholar
• Jermain DM, Preece CK, Sykes FL, Kuehl TJ, Sulak PJ. Luteal phase sertraline treatment for premenstrual dysphoric disorder. Arch. Fam. Med.8, 328–332 (1999).
   PubMedGoogle Scholar
• Harrison WM, Endicott J, Nee J. Treatment of premenstrual dysphoria with alprazolam. Arch. Gen. Psychiatry47, 270–275 (1990).
   PubMed Web of Science ®Google Scholar
• Berger CP, Presser B. Alprazolam in the treatment of two subsamples of patients with late luteal phase dysphoric disorder. Obstet. Gynecol.84, 379–385 (1994).
   PubMed Web of Science ®Google Scholar
• Smith S, Rinehart JS, Ruddock VE, Schiff I. Treatment of premenstrual syndrome with alprazolam: results of a double blind, placebo placebo-controlled, randomized crossover clinical trial. Obstet. Gynecol.70, 37–43 (1987).
   PubMed Web of Science ®Google Scholar
• Schmidt PJ, Grover GN, Rubinow DR. Alprazolam in the treatment of premenstrual syndrome: a double-blind, placebo controlled trial. Arch. Gen. Psychiatry50, 467–473 (1993).
   PubMed Web of Science ®Google Scholar
• Freeman EW, Rickels K, Sondheimer SJ, Polansky M. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA274, 51–57 (1995).
   PubMed Web of Science ®Google Scholar
• Steiner M. Premenstrual syndrome, premenstrual dysphoric disorder, and beyond: a clinical primer for practitioners. Obstet. Gynecol.104, 845 (2004).
   PubMed Web of Science ®Google Scholar
• Freeman EW. Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder. CNS Drugs18, 453 (2004).
   PubMed Web of Science ®Google Scholar
• Carman JS, Crews E, Bancroft A et al. Calcium and calcium regulating hormones in the biphasic periodic psychoses. J. Operational Psychiatry11, 5–17 (1980).
   Google Scholar
• Linder J, Brimar K, Granberg PO, Wetterberg L, Werner S. Characteristic changes in psychiatric symptoms, cortisol and melatonin but not prolactin in primary hyperparathyroidism. Acta Psychiatr. Scand.7, 32–40 (1988).
   Google Scholar
• Okamoto T, Gerstein HC, Obara T. Psychiatric symptoms, bone density and non-specific symptoms in patients with mild hypercalcemia due to primary hyperparathyroidism. Endocr. J.44, 367–374 (1997).
   PubMed Web of Science ®Google Scholar
• Joborn C, Hetta J, Palmer M, Akerstrom G, Ljunghall S. Psychiatric symptomatology in patients with primary hyperparathyroidism. Ups. J. Med. Sci.91, 77–87 (1986).
   PubMed Web of Science ®Google Scholar
• Joborn C, Hetta J, Johsnsson H et al. Psychiatric morbidity in primary hyperparathyroidism. World J. Surg.12, 476–481 (1988).
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Lee J, Prinz RA. Major depression due to primary hyperparathyroidism: a frequent and correctable disorder. Am. Surg.70(2), 175–179 (2004).
   PubMed Web of Science ®Google Scholar
• Bohrer T, Pasteur I, Lyutkevych O et al. Permanent postoperative hypoparathyroidism. An epidemiological clinical study using a new questionnaire instrument. J. Ukrainian Acad. Sci.9, 476–494 (2003).
   Google Scholar
• Kamei K, Tabata O, Muneoka K, Muraoka SI, Tomiyoshi R, Takigawa M. Electrolytes in erythrocytes of patients with depressive disorders. Psychiatry Clin. Neurosci.52(5), 529–331 (1998).
   PubMed Web of Science ®Google Scholar
• Konopka LM, Cooper R, Crayton JW. Serotonin-induced increases in platelet cytosolic calcium concentration in depressed, schizophrenic, and substance abuse patients. Biol. Psychiatry39(8), 708–713 (1996).
   PubMed Web of Science ®Google Scholar
• Mikuni M, Kagaya A, Takahashi K, Meltzer HY. Serotonin but not norepinephrine-induced calcium mobilization of platelets is enhanced in affective disorders. Psychopharmacology106(3), 311–314 (1992).
   PubMed Web of Science ®Google Scholar
• Matsubara S, Matsubara R, Kusumi I, Koyama T, Yamashita I. Dopamine D1, D2 and serotonin2 receptor occupation by typical and atypical antipsychotic drugs in vivo. J. Pharmacol. Exp. Ther.265(2), 498–508 (1993).
   PubMed Web of Science ®Google Scholar
• Plein H, Berk M, Eppel S, Butkow N. Augmented platelet calcium uptake in response to serotonin stimulation in patients with major depression measured using Mn2+ influx and 45Ca2+ uptake. Life Sci.66(5), 425–431 (2000).
   PubMed Web of Science ®Google Scholar
• Dubovsky S. Calcium channel antagonists as novel agents for the treatment of bipolar disorder. In: Textbook of Psychopharmacology. Schatzberg A, Nemeroff CB (Eds). American PsychiatricPress, Inc., Washington, DC, USA 455–469 (1998).
   Google Scholar
• Dubovsky S, Murphy J, Thomas M, Rademacher J. Abnormal intracellular calcium ion concentration in platelets and lymphocytes of bipolar patients. Am. J. Psychiatry149, 118–120 (1992).
   PubMed Web of Science ®Google Scholar
• Dubovsky SL, Christiano J, Daniell LC et al. Increased platelet intracellular calcium concentration in patients with bipolar affective disorders. Arch. Gen. Psychiatry46, 632–638 (1989).
   PubMed Web of Science ®Google Scholar
• Levy NA, Janicak PG. Calcium channel antagonists for the treatment of bipolar disorder. Bipolar Disorders2, 108–119 (2000).
   PubMed Web of Science ®Google Scholar
• Barden N, Harvey M, Gagne B et al. Analysis of single nucleotide polymorphisms in genes in the chromosome 12Q24.31 region points to P2RX7 as a susceptibility gene to bipolar affective disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet.141, 374–382 (2006).
   Web of Science ®Google Scholar
• Lucae S, Salyakina D, Barden N et al.P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder. Hum. Mol. Genet.15, 2438–2445 (2006).
   PubMed Web of Science ®Google Scholar
• Kenny AD. Vitamin D metabolism: physiological regulation in egg laying Japanese quail. Am. J. Physiol.230, 1609–1611 (1976).
   PubMedGoogle Scholar
• Tanaka Y, Castillo L, Deluca HF. Control of renal vitamin D hydroxylases in birds by sex hormones. Proc. Natl Acad. Sci. USA73, 2701–2705 (1976).
   PubMed Web of Science ®Google Scholar
• Brommage R, Binacua C, Carrie AL. Ovulation-associated increase in intestinal calcium absorption during the rat estrous cycle is blunted by ovariectomy. Biol. Reprod.49, 544–548 (1993).
   PubMed Web of Science ®Google Scholar
• Cressent M, Elie C, Taboulet J, Moukhtar MS, Milhaud G. Calcium regulating hormones during the estrous cycle of the rat. Proc. Soc. Exp. Biol. Med.172, 158–162 (1983).
   PubMed Web of Science ®Google Scholar
• Hotchkiss CE, Brommage R. Changes in bone turnover during the menstrual cycle in cynomolgus monkeys. Calcif. Tissue Int.66, 224–228 (2000).
   PubMed Web of Science ®Google Scholar
• Okey R, Stewert JM, Greenwood ML. Studies of the metabolism of women: the calcium and inorganic phosphorus in the blood of normal women at the various stages of the monthly cycle. J. Biol. Chem.4, 91–102 (1930).
   Google Scholar
• Pitkin R, Reynolds WA, Williams GA, Hargis GK. Calcium regulating hormones during the menstrual cycle. J. Clin. Endocrinol. Metab.47, 626 (1978).
   PubMed Web of Science ®Google Scholar
• Gray TK, McAdoo T, Hatley L, Lester GE, Thierry M. Fluctuation of serum concentration of 1,25 dihydroxyvitamin D during the menstrual cycle. Am. J. Obstet. Gynecol.144, 880 (1982).
   PubMed Web of Science ®Google Scholar
• Tjellesen L, Christiansen C, Hummer L, Larsen NE. Unchanged biochemical indices of bone turnover despite fluctuations in 1,25 dihydroxyvitamin D during the menstrual cycle. Acta Endocrinologica102, 476 (1983).
   PubMedGoogle Scholar
• Buchanan J, Santen R, Cavaliere A, Cauffman S, Greer R, Demers L. Interaction between parathyroid hormone and endogenous estrogen in normal women. Metabolism35, 489–494 (1986).
   PubMed Web of Science ®Google Scholar
• Muse KN, Manolagas SC, Deftos LJ, Alexander N, Yen SS. Calcium-regulating hormones across the menstrual cycle. J. Clin. Endocrinol. Metab.62(6), 1313–1316 (1986).
   PubMed Web of Science ®Google Scholar
• Baran DT, Whyte MP, Haussler MR et al. Effect of the menstrual cycle on calcium regulating hormones in the normal young woman. J. Clin. Endocrinol. Metab.50, 377–379 (1980).
   PubMed Web of Science ®Google Scholar
• Nielsen HK, Brixen K, Bouillon R, Mosekilde L. Changes in biochemical markers of osteoblastic activity during the menstrual cycle. J. Clin. Endocrinol. Metab.70, 1431–1437 (1990).
   PubMed Web of Science ®Google Scholar
• Gorai I, Taguchi Y, Chaki O et al. Serum soluble interleukin-6 receptor and biochemical markers of bone metabolism show significant variations during the menstrual cycle. J. Clin. Endocrinol. Metab.83, 326–332 (1998).
   PubMed Web of Science ®Google Scholar
• Gorai I, Chaki O, Nakayama M, Minaguchi H. Urinary biochemical markers for bone resorption during the menstrual cycle. Calcif. Tissue Int.57, 100–104 (1995).
   PubMed Web of Science ®Google Scholar
• Zittermann A, Schwarz I, Scheld K et al. Physiologic fluctuations of serum estradiol levels influence biochemical markers of bone resorption in young women. J. Clin. Endocrinol. Metab.85(1), 95–101 (2000).
   PubMed Web of Science ®Google Scholar
• Pietras RJ, Szego CM. Endometrial cell calcium and oestrogen action. Nature253, 357–359 (1975).
   PubMed Web of Science ®Google Scholar
• Perret S, Dockery P, Harvey BJ. 17β-oestradiol stimulates capacitative Ca2+ entry in human endometrial cells. Mol. Cell. Endocrinol.176(1–2), 77–84 (2001).
   PubMed Web of Science ®Google Scholar
• Thys-Jacobs S, Alvir MJ. Calcium-regulating hormones across the menstrual cycle: evidence of a secondary hyperparathyroidism in women with PMS. J. Clin. Endocrinol. Metab.80(7), 2227–2232 (1995).
   PubMed Web of Science ®Google Scholar
• Thys-Jacobs S, Ceccarelli S, Bierman A, Weisman H, Cohen MA, Alvir J. Calcium supplementation in premenstrual syndrome: a randomized crossover trial. J. Gen. Intern. Med.4(3), 183–189 (1989).
   PubMed Web of Science ®Google Scholar
• Penland JG, Johnson PE. Dietary calcium and manganese effects on menstrual cycle symptoms. Am. J. Obstet. Gynecol.168(5), 1417–1423 (1993).
   PubMed Web of Science ®Google Scholar
• Thys-Jacobs S, Starkey P, Bernstein D, Tian J. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am. J. Obstet. Gynecol.179(2), 444–452 (1998).
   PubMed Web of Science ®Google Scholar
• Bertone-Johnson ER, Hankinson SE, Bendich A, Johnson SR, Willett WC, Manson JE. Calcium and vitamin D intake and risk of incident premenstrual syndrome. Arch. Intern. Med.165(11), 1246–1252 (2005).
   PubMed Web of Science ®Google Scholar
• Dickerson L, Mazyck PJ, Hunter MH. Premenstrual syndrome. Am. Fam. Physician67(8), 1743–1752 (2003).
   PubMed Web of Science ®Google Scholar
• Maalouf J, Nabulsi M, Vieth R et al. Short- and long-term safety of weekly high-dose vitamin D3 supplementation in school children. J. Clin. Endocrinol. Metab.93, 2693–2701 (20082008).
   PubMed Web of Science ®Google Scholar